PMDD: getting a diagnosis, being believed, and the treatment conversation you deserve

What PMDD actually is

PMDD was formally recognised as a depressive disorder in the DSM-5 in 2013 (American Psychiatric Association, 2013). To meet the criteria, at least five symptoms need to appear in the final week before your period, start to improve within a few days of bleeding, and become minimal or absent in the week after. At least one has to be a core mood symptom: marked mood swings or sudden tearfulness, irritability or anger, low mood or hopelessness, or anxiety and tension. The others can include losing interest in things you usually love, poor concentration, exhaustion, cravings, sleeping too much or too little, feeling overwhelmed, and physical symptoms like breast tenderness and bloating.

Estimates vary with how strictly the criteria are applied, but roughly 2 to 6 per cent of women who menstruate meet them (Epperson et al., 2012). That is a lot of women quietly losing a quarter of every month.

The part most people get wrong is the biology. PMDD is not usually a hormone 'imbalance' in the sense of hormone levels being too high or too low. In a landmark experiment, researchers switched off the ovaries of women with severe premenstrual symptoms and their symptoms disappeared; when estradiol or progesterone was added back, symptoms returned — but the same hormones had no such effect on women without PMS (Schmidt et al., 1998). Later work found differences in how cells from women with PMDD respond to sex hormones at a genetic level (Dubey et al., 2017). The best current explanation is a differing brain sensitivity to normal hormonal change, including to allopregnanolone, a calming progesterone metabolite that some women with PMDD appear to react to paradoxically (Bäckström et al., 2014).

In most women with PMDD, hormone levels are normal. It is the brain's response to normal hormonal change that differs — which is exactly why a single blood test can't diagnose it.

Why getting diagnosed is so hard

There is no blood test or scan for PMDD. Diagnosis depends on the pattern of symptoms over time, and that pattern is invisible in a ten-minute appointment that happens to fall on a good week. The symptoms also overlap with depression, anxiety, bipolar disorder and ADHD, and some women have premenstrual exacerbation of an existing condition, which is managed differently from PMDD. Untangling these takes careful history-taking that busy services rarely have time for.

Memory doesn't help either. When women are asked to recall their symptoms after the fact, the picture is often less accurate than daily ratings collected at the time, which is why the DSM-5 requires prospective tracking across at least two symptomatic cycles (Eisenlohr-Moul et al., 2017). And there is a well-documented pattern of women's symptoms being attributed to emotional causes more readily than men's (Samulowitz et al., 2018).

This matters because PMDD is not trivial. A systematic review found that suicidal thoughts are more common in women with PMDD than in women without it (Osborn et al., 2021). Being believed is not a nicety; it is a safety issue.

Track before you talk: two cycles of evidence

The single most useful thing you can do before an appointment is to collect your own data. The Daily Record of Severity of Problems (DRSP) is a free, validated chart used in PMDD research (Endicott et al., 2006); you score each symptom from one to six every evening. A cycle-tracking app works too, as long as you can export or print it. Alongside it, I like clients to keep a short symptoms journal, because numbers show the pattern and words show the impact.

• Mark day one of every period clearly. The whole case rests on symptoms lining up with the luteal phase.
• Rate your mood, irritability, anxiety, energy, sleep, cravings and physical symptoms every day — including the good days. The good days are the evidence.
• Write one or two lines about what the symptoms cost you: the argument, the missed deadline, the day you couldn't leave the house.
• Note anything frightening honestly, including intrusive or suicidal thoughts. You can choose how to share it, but the record should be true.
• Track for at least two full cycles, ideally three, before you go.
• Bring a one-page summary: your average cycle length, which days symptoms start and stop, and your three worst symptoms.

Book the appointment for the version of you who can advocate

This sounds small, and it is one of the most practical pieces of advice I give. If you can, book the appointment for your follicular phase or around ovulation — roughly the week after your period ends, when most women with PMDD feel clearest and most capable. You will remember what you meant to say, you will be less likely to be talked down, and you will be in a better position to weigh up options calmly.

Take someone with you if you can: a partner, friend or family member who has seen the luteal version of you. An advocate can describe changes you may not fully see yourself, take notes, and gently say, 'I don't think that answers her question.'

• Send your summary ahead of the appointment if the practice allows it.
• Open with the pattern, not the worst day: 'For five months, these symptoms have started around day 20 and gone by day 2.'
• Write down your top three questions and ask them first.
• Ask directly: 'Could this be PMDD? What else could it be, and how would we rule those out?'
• Ask for the discussion to be recorded in your notes, and for a referral to a gynaecologist or psychiatrist with PMDD experience if your GP isn't confident.

The treatment conversation many women aren't offered

Many women with PMDD are offered an antidepressant, told it's stress, or both — and the conversation ends there. Antidepressants have a genuine place: SSRIs are one of the best-evidenced treatments for severe premenstrual symptoms, and in PMDD they often work within days and can sometimes be taken in the luteal phase only (Marjoribanks et al., 2013). For some women they are exactly the right tool. But because PMDD is a hormone-sensitive condition, it is reasonable to expect a conversation that also covers hormonal approaches. The UK's Royal College of Obstetricians and Gynaecologists guideline sets out a stepped range of options, from lifestyle measures and CBT through to hormonal suppression of the cycle (RCOG, 2016).

Hormonal options that may be discussed include certain combined pills taken continuously, some of which contain drospirenone and have modest evidence in PMDD (Lopez et al., 2012); transdermal estradiol to suppress ovulation, which requires a progestogen to protect the womb lining (Watson et al., 1989); and GnRH analogues, which switch the cycle off and are sometimes used as a diagnostic test as well as a treatment, usually with 'add-back' hormones (Wyatt et al., 2004).

What about body-identical progesterone? I want to be honest here, because this is where the internet gets ahead of the evidence. A Cochrane review did not find clear evidence that progesterone is an effective treatment for premenstrual syndrome (Ford et al., 2012). And because sensitivity to progesterone and its metabolites appears to be part of the problem in PMDD, some women feel worse on progesterone or synthetic progestogens rather than better — including the progestogen needed alongside estradiol. Some women do report benefit, and practitioners experienced in this area may discuss it, but it is an individual trial with careful monitoring, not a proven fix.

No hormone, pill or supplement is a guaranteed cure for PMDD, and none should be framed as life-saving. What you deserve is a conversation that includes all the evidence-based options — and a practitioner who will adjust the plan with you.

Where nutrition and lifestyle fit alongside medical care

Nutrition is not a replacement for medical treatment in PMDD, but it can be a meaningful part of the picture — and in my experience it often makes whichever medical route you choose work better. The evidence is mixed in places, so here is what I lean on and how confident I am.

• Calcium has one of the better trial bases: 1,200 mg a day reduced premenstrual symptoms compared with placebo in a large randomised trial (Thys-Jacobs et al., 1998). Food sources include full-fat organic dairy (or A2, sheep or goat alternatives), sardines with bones, tahini and leafy greens.
• Vitamin B6 showed some benefit in a systematic review, though trial quality was variable (Wyatt et al., 1999). High doses over long periods can damage nerves, so use it only under guidance.
• Chasteberry (Vitex agnus-castus) has some supportive trials for premenstrual symptoms (van Die et al., 2013), but it acts on hormones and isn't suitable alongside hormonal contraception or in pregnancy without advice.
• Steady blood sugar — protein and fibre at every meal, no long gaps in the luteal phase — is a sensible foundation, although PMDD-specific trials are limited.
• Reducing alcohol and caffeine in the luteal phase is a reasonable experiment; the evidence is limited, so let your own tracking tell you whether it helps.
• Regular movement, consistent sleep and CBT-based approaches have some supporting evidence, although psychological trials in this area are small (Busse et al., 2009).
• It is worth checking ferritin, thyroid function, vitamin D and B12, because deficiencies and thyroid problems can worsen fatigue and mood and are easy to miss.

If you are struggling right now

If you are having thoughts of harming yourself or ending your life, please reach out now: in the UK call Samaritans on 116 123 (free, 24/7); in South Africa call the SADAG suicide crisis line on 0800 567 567; or contact your local emergency services. You deserve support today, not after the next appointment.

The International Association for Premenstrual Disorders (IAPMD) offers free education and peer support for people with PMDD and the people who love them. Knowing you are not the only one can make the next appointment easier to face.

Before you act on any of this

This article is for education and general information only. It isn't medical advice, it can't diagnose or treat any condition, and it doesn't replace a consultation with your own doctor or a qualified practitioner who knows your history. Please don't start, stop or change any medication, hormone or supplement because of something you've read here — take your questions to the person responsible for your care.

Hormonal treatments for PMDD carry individual risks and side effects. Whether any of them is right for you is a decision to make with a qualified practitioner who knows your full medical and family history.

References

• American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA: APA.
• Bäckström, T., Bixo, M., Johansson, M., et al. (2014). Allopregnanolone and mood disorders. Progress in Neurobiology, 113, 88–94.
• Busse, J.W., Montori, V.M., Krasnik, C., Patelis-Siotis, I., & Guyatt, G.H. (2009). Psychological intervention for premenstrual syndrome: a meta-analysis of randomized controlled trials. Psychotherapy and Psychosomatics, 78(1), 6–15.
• Dubey, N., Hoffman, J.F., Schuebel, K., et al. (2017). The ESC/E(Z) complex, an effector of response to ovarian steroids, manifests an intrinsic difference in cells from women with premenstrual dysphoric disorder. Molecular Psychiatry, 22(8), 1172–1184.
• Eisenlohr-Moul, T.A., Girdler, S.S., Schmalenberger, K.M., et al. (2017). Toward the reliable diagnosis of DSM-5 premenstrual dysphoric disorder: the Carolina Premenstrual Assessment Scoring System (C-PASS). American Journal of Psychiatry, 174(1), 51–59.
• Endicott, J., Nee, J., & Harrison, W. (2006). Daily Record of Severity of Problems (DRSP): reliability and validity. Archives of Women's Mental Health, 9(1), 41–49.
• Epperson, C.N., Steiner, M., Hartlage, S.A., et al. (2012). Premenstrual dysphoric disorder: evidence for a new category for DSM-5. American Journal of Psychiatry, 169(5), 465–475.
• Ford, O., Lethaby, A., Roberts, H., & Mol, B.W.J. (2012). Progesterone for premenstrual syndrome. Cochrane Database of Systematic Reviews, (3), CD003415.
• Lopez, L.M., Kaptein, A.A., & Helmerhorst, F.M. (2012). Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database of Systematic Reviews, (2), CD006586.
• Marjoribanks, J., Brown, J., O'Brien, P.M.S., & Wyatt, K. (2013). Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database of Systematic Reviews, (6), CD001396.
• Osborn, E., Brooks, J., O'Brien, P.M.S., & Wittkowski, A. (2021). Suicidality in women with premenstrual dysphoric disorder: a systematic literature review. Archives of Women's Mental Health, 24(2), 173–184.
• Royal College of Obstetricians and Gynaecologists. (2016). Management of premenstrual syndrome. Green-top Guideline No. 48. BJOG, 124, e73–e105.
• Samulowitz, A., Gremyr, I., Eriksson, E., & Hensing, G. (2018). 'Brave men' and 'emotional women': a theory-guided literature review on gender bias in health care and gendered norms towards patients with chronic pain. Pain Research and Management, 2018, 6358624.
• Schmidt, P.J., Nieman, L.K., Danaceau, M.A., Adams, L.F., & Rubinow, D.R. (1998). Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. New England Journal of Medicine, 338(4), 209–216.
• Thys-Jacobs, S., Starkey, P., Bernstein, D., & Tian, J. (1998). Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. American Journal of Obstetrics and Gynecology, 179(2), 444–452.
• van Die, M.D., Burger, H.G., Teede, H.J., & Bone, K.M. (2013). Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials. Planta Medica, 79(7), 562–575.
• Watson, N.R., Studd, J.W., Savvas, M., Garnett, T., & Baber, R.J. (1989). Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. The Lancet, 2(8665), 730–732.
• Wyatt, K.M., Dimmock, P.W., Jones, P.W., & O'Brien, P.M.S. (1999). Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ, 318(7195), 1375–1381.
• Wyatt, K.M., Dimmock, P.W., Ismail, K.M.K., Jones, P.W., & O'Brien, P.M.S. (2004). The effectiveness of GnRHa with and without 'add-back' therapy in treating premenstrual syndrome: a meta-analysis. BJOG, 111(6), 585–593.